In AD, PGSs may explain additional disease risk beyond the apolipoprotein E (APOE) locus and have been associated with age of onset, disease progression, and clinical measures such as cognitive decline and biofluid and neuroimaging biomarkers.4, 5, 6, 7, 8, 9, 10. This evidence concerns the gene APOE and Alzheimer disease.